Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michio Oda is active.

Publication


Featured researches published by Michio Oda.


Journal of Hepatology | 1999

Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-κB activation in rat hepatocytes

Masaki Kaibori; Kazushige Sakitani; Michio Oda; Yasuo Kamiyama; Yasuo Masu; Mikio Nishizawa; Seiji Ito; Tadayoshi Okumura

BACKGROUND/AIMS Recent evidence indicates that an increase in nitric oxide production after liver transplantation is associated with acute allograft rejection. Nitric oxide mediates cellular injury under various pathological conditions in the liver. Studies were performed to determine whether the immunosuppressants FK506 and cyclosporin A directly influence gene expression of inducible nitric oxide synthase by interleukin 1beta in hepatocytes. METHODS Primary cultures of rat hepatocytes were treated with interleukin 1beta in the presence and absence of FK506 or cyclosporin A. Release of nitrite (nitric oxide metabolite) into culture medium, levels of inducible nitric oxide synthase protein and mRNA, and activation of nuclear factor-kappaB were compared with the two drugs. RESULTS Interleukin 1beta increased levels of inducible nitric oxide synthase protein and inducible nitric oxide synthase mRNA, as well as nitric oxide production, in the cultured hepatocytes. Nuclear factor-kappaB, an important transcription factor in inducible nitric oxide synthase gene expression in response to inflammation, also appeared in the nuclear fraction of hepatocytes after addition of interleukin 1beta. FK506 markedly inhibited the nitric oxide formation, inducible nitric oxide synthase protein synthesis and inducible nitric oxide synthase mRNA expression induced by interleukin 1beta, but cyclosporin A had no effects. Furthermore, FK506 inhibited nuclear factor-kappaB activation and decreased mRNA levels of the p50/p65 subunits of nuclear factor-kappaB. CONCLUSIONS These results demonstrate that FK506, but not cyclosporin A, inhibits the induction of inducible nitric oxide synthase expression during nuclear factor-kappaB activation. FK506 may influence liver function during diseases by modulating the nitric oxide pathway, in addition to its immunosuppressive effect.


Journal of Biological Chemistry | 2000

Vicinal dithiol-binding agent, phenylarsine oxide, inhibits inducible nitric-oxide synthase gene expression at a step of nuclear factor-kappaB DNA binding in hepatocytes.

Michio Oda; Kazushige Sakitani; Masaki Kaibori; Tomohisa Inoue; Yasuo Kamiyama; Tadayoshi Okumura

Inflammatory cytokine interleukin 1β induces inducible nitric-oxide synthase (iNOS) mRNA and its protein, which are followed by increasing the production of nitric oxide, in primary cultures of rat hepatocytes. Nuclear factor-κB (NF-κB), an important transcription factor for iNOS gene expression, is also activated and translocated to the nucleus. In the present study, we found that vicinal dithiol-binding agent, phenylarsine oxide (PAO), inhibited the induction of iNOS protein and mRNA as well as the release of nitrite (nitric oxide metabolite) into the culture medium. Simultaneous addition of a vicinal dithiol compound, 2,3-dimercaptopropanol, with PAO completely abolished these inhibitions. PAO could not prevent either degradation of an inhibitory protein, IκB, of NF-κB or translocation of NF-κB to the nucleus. However, electrophoretic mobility shift assay demonstrated that PAO decreased the interaction between NF-κB and its binding consensus oligonucleotide. Transfection experiments with iNOS promoter-luciferase construct revealed that PAO inhibited NF-κB binding to DNA. These results indicate that PAO inhibits iNOS gene expression at a step of NF-κB binding to DNA by modifying its vicinal dithiol moiety, which may play a crucial role for the iNOS regulation in hepatocytes.


Annals of Surgery | 1999

Acceptance of Skin Allografts in Pigs by Portal Venous Injection of Donor Bone Marrow Cells

Haruo Morita; Noboru Nakamura; Kikuya Sugiura; Sohei Satoi; Yohei Sakakura; Wei Tu; Kazumasa Yoshida; Michio Oda; Tomohisa Inoue; Hiroyuki Inui; Takashi Nagahama; Yasuo Kamiyama; Susumu Ikehara

OBJECTIVE To confirm in pigs whether a new method for organ allografts, originally established in mice by the authors, might be applicable to humans. SUMMARY BACKGROUND DATA The authors recently established a new method for organ allografts in mice that includes the injection of donor bone marrow cells (BMCs) using the portal vein (PV), followed by the administration of cyclosporin A (CsA) on days 2 and 5, and the intravenous injection of BMCs on day 5. In the present study, they modify this method (a single-day protocol) and apply it to pigs. METHODS Allogeneic BMCs of donor pigs were injected using the PV (a superior mesenteric vein). The skin grafting was carried out on the day of the PV injection. The recipient pigs received donor grafts, autologous grafts, and third-party grafts at the same time. In addition, an open wound was made as the epithelized control. Full-thickness skin grafts were harvested from the dorsal wall of the donors. CsA (10 mg/kg) was injected intramuscularly into recipient pigs on days 2 and 5 after the PV injection. RESULTS One hundred percent of skin grafts survived for >300 days when donor BMCs were injected using the PV (n = 6). However, the skin grafts of the three pigs that had received BMCs using the intravenous route were rejected within 3 to 4 weeks after transplantation. The third-party skin grafts showed necrotic changes on day 21 after transplantation. CONCLUSIONS One hundred percent of skin allografts can be obtained, even in pigs, by injecting donor BMCs using the PV, carrying out skin allografts, and administering CsA on days 2 and 5. This single-day protocol would be of great advantage for human organ transplantation.


Digestive Diseases and Sciences | 2015

Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma

Masaki Kaibori; Nobuaki Shikata; Tatsuma Sakaguchi; Morihiko Ishizaki; Kosuke Matsui; Hiroya Iida; Yoshito Tanaka; Hirokazu Miki; Richi Nakatake; Tadayoshi Okumura; Katsuji Tokuhara; Kentaro Inoue; Jouji Wada; Michio Oda; Mikio Nishizawa; Masanori Kon

BackgroundAberrant signaling mediated by the mammalian target of rapamycin (mTOR) occurs at high frequency in hepatocellular carcinoma (HCC), indicating that mTOR is a candidate for targeted therapy. mTOR forms two complexes called mTORC1 (mTOR complexed with raptor) and mTORC2 (mTOR complexed with rictor). There are minor studies of the expression kinetics of mTORC1 and mTORC2 in HCC.MethodsWe studied 62 patients with HCC who underwent curative resection. We used univariate and multivariate analyses to identify factors that potentially influence disease and overall survival after hepatectomy. The mRNA and protein levels of mTOR, rictor and raptor in cancer and non-cancer tissues were analyzed using quantitative RT-PCR, immunohistochemistry and Western blotting.Results/ConclusionHigh ratio of the levels of rictor and raptor mRNAs in tumors was identified as independent prognostic indicators for disease-free survival. Low and high levels of preoperative serum albumin and mTOR mRNA in the tumor, respectively, were identified as independent indicators of overall survival. HCC is likely to recur early after hepatic resection in patients with high levels of mTOR and rictor mRNAs and high rictor/raptor ratios in cancer tissues. We conclude that analysis of mTOR expression in cancer tissues represents an essential strategy to predict HCC recurrence after curative treatment.


Shock | 2000

Increased extra domain-A containing fibronectin and hepatic dysfunction during septic response: an in vivo and in vitro study.

Sohei Satoi; Hiroaki Kitade; Yoshifumi Hiramatsu; A-Hon Kwon; Hakuo Takahashi; Kiyotoshi Sekiguchi; Masanori Uehara; Michio Oda; Yasuaki Yanagimoto; Keiichi Miyashita; Eiji Sakashita; Yasuo Kamiyama

A massive inflammatory reaction resulting from systemic cytokine release is the common pathway underlying sepsis or multiple organ dysfunction. The role of extra domain sequence A-containing fibronectin (EDA+FN) formation during the septic response is not known. The present study investigates the role of EDA+FN during the septic response under in vitro and in vivo conditions. The direct effects of interleukin-1, interleukin-6, and tumor necrosis factor-alpha on EDA+FN production were evaluated in primary cultured human hepatocytes and fibroblasts. Serial plasma EDA+FN levels were measured using an enzyme-linked immunosorbent assay in 24 patients who developed postoperative sepsis following general abdominal surgery of which there were 17 survivors and 7 non-survivors. EDA+FN secretion was significantly increased in cultured hepatocytes but not fibroblasts at 24 and 48 h following exposure to IL-1 compared to controls. In the clinical setting plasma EDA+FN levels in non-survivors were significantly higher than in survivors. Moreover, the EDA+FN levels were correlated closely with liver function tests. EDA+FN levels may represent a specific marker of vascular injury or systemic inflammatory response syndrome that is associated with an adverse clinical outcome.


Hepatology | 2000

Hypoxia and Heat Inhibit Inducible Nitric Oxide Synthase Gene Expression by Different Mechanisms in Rat Hepatocytes

Tomohisa Inoue; A-Hon Kwon; Michio Oda; Masaki Kaibori; Yasuo Kamiyama; Mikio Nishizawa; Seiji Ito; Tadayoshi Okumura


Life Sciences | 2001

FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes.

Masaki Kaibori; Tomohisa Inoue; Wei Tu; Michio Oda; A-Hon Kwon; Yasuo Kamiyama; Tadayoshi Okumura


Hepatology | 1998

Hepatocyte growth factor stimulates synthesis of lipids and secretion of lipoproteins in rat hepatocytes.

Masaki Kaibori; A‐H. Kwon; Michio Oda; Yasuo Kamiyama; Naomi Kitamura; Tadayoshi Okumura


Journal of Surgical Research | 2002

Impairment of Activation of Hepatocyte Growth Factor Precursor into Its Mature Form in Rats with Liver Cirrhosis

Masaki Kaibori; Tomohisa Inoue; Yohei Sakakura; Michio Oda; Takashi Nagahama; A-Hon Kwon; Yasuo Kamiyama; Keiji Miyazawa; Tadayoshi Okumura


Biochemical and Biophysical Research Communications | 2002

Exogenously Administered HGF Activator Augments Liver Regeneration through the Production of Biologically Active HGF

Masaki Kaibori; Tomohisa Inoue; Michio Oda; Daiji Naka; Toshiya Kawaguchi; Naomi Kitamura; Keiji Miyazawa; A-Hon Kwon; Yasuo Kamiyama; Tadayoshi Okumura

Collaboration


Dive into the Michio Oda's collaboration.

Top Co-Authors

Avatar

Yasuo Kamiyama

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Masaki Kaibori

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tomohisa Inoue

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

A-Hon Kwon

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar

Yohei Sakakura

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Seiji Ito

Kansai Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Wei Tu

Kansai Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge